News | August 14, 2024
Marksans Pharma Q1 FY25 revenue up 18%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
This acquisition enables MTD to open new, strategic markets
Subscribe To Our Newsletter & Stay Updated
